BioSpace News Archive

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open.

Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology today announced that it will be presenting at the upcoming Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023), to be held in San Diego and virtually November 1-5, 2023.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM).

NKILT Therapeutics, Inc., a preclinical-stage cell therapy biotech company developing proprietary Chimeric ILT-Receptor (CIR™)–engineered natural killer (NK) cell therapies, announced today that preclinical data of the CIR™NK cells have been selected for an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, being held December 9-12, 2023.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced additional data from two pivotal clinical studies demonstrating sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, from November 10-14, 2023.

Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone.

The company’s application to start a clinical phase I/IIa study in Australia with the candidate drug in the radionuclide therapy program Tumorad, 177Lu-SN201, has been approved.

In Norway, Carbonhand has been prescribed as a medical device through the public reimbursement system for several years.

T3D Therapeutics presented top-line results from its Phase 2 PIONEER study at the 16th international conference on Clinical Trials in Alzheimer’s Disease.